Literature DB >> 33689078

Usefulness of Neutrophil to Lymphocyte Ratio at Recurrence for Predicting Long-Term Outcomes in Patients with Recurrent Esophageal Squamous Cell Carcinoma.

Shota Hoshino1, Masashi Takeuchi1, Hirofumi Kawakubo2, Satoru Matsuda1, Shuhei Mayanagi1, Tomoyuki Irino1, Kazumasa Fukuda1, Rieko Nakamura1, Norihito Wada1, Yuko Kitagawa1.   

Abstract

BACKGROUND: Although radical esophagectomy with multifield lymph node dissection is a promising treatment to achieve long-term survival for resectable esophageal cancer, survival after postoperative recurrence remains poor. To select the optimal treatment for patients with recurrent esophageal cancer, simple, objective indicators for predicting of long-term outcomes are needed. PATIENTS AND METHODS: We conducted a single-institution, retrospective cohort study between 2004 and 2019, wherein 586 patients underwent transthoracic esophagectomy for primary esophageal squamous cell carcinoma. Of these, 133 patients with postoperative recurrence were included in this analysis. Several predictors of survival after recurrence were investigated.
RESULTS: Among all patients, the 1- and 3-year survival rates after recurrence were 48.0% and 23.1%, respectively. On multivariate analysis, the neutrophil to lymphocyte ratio (NLR) at recurrence was identified as a significant predictor of death after recurrence (hazard ratio 1.061; 95% confidence interval 1.002-1.125; p = 0.043). Time-dependent receiver operating characteristics curves showed that the area under the curve value of the NLR at recurrence was superior to the modified Glasgow Prognostic Score at recurrence in all terms. To simulate the clinical decision process, we set the cut-off NLR at recurrence for survival using survival classification and regression tree (CART) and defined the optimal cut-off value as 3.374.
CONCLUSIONS: NLR at recurrence was a significant indicator of survival after recurrence in patients with recurrent esophageal cancer. CART analysis was used to determine the optimal cut-off value for the prediction of survival, allowing the NLR to be used clinically to facilitate decision making.

Entities:  

Mesh:

Year:  2021        PMID: 33689078     DOI: 10.1245/s10434-021-09637-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2019-04-01       Impact factor: 5.344

3.  Perioperative risk calculator for distal gastrectomy predicts overall survival in patients with gastric cancer.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Yoshiyuki Suzuki; Koji Okabayashi; Toshiki Yamashita; Satoshi Kamiya; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Koichi Suda; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Gastric Cancer       Date:  2018-11-26       Impact factor: 7.370

4.  Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

5.  Survival benefit of multimodal local therapy for repeat recurrence of thoracic esophageal squamous cell carcinoma after esophagectomy.

Authors:  Itasu Ninomiya; Koichi Okamoto; Sachio Fushida; Jun Kinoshita; Hiroyuki Takamura; Hidehiro Tajima; Isamu Makino; Tomoharu Miyashita; Tetsuo Ohta
Journal:  Esophagus       Date:  2018-08-28       Impact factor: 4.230

  5 in total
  2 in total

1.  The Prognostic Role of the Neutrophil to Lymphocyte Ratio at Recurrence in Esophageal Squamous Cell Carcinoma: Challenges and Future Directions.

Authors:  Audrey E Kam; Ashiq Masood
Journal:  Ann Surg Oncol       Date:  2021-02-09       Impact factor: 5.344

2.  Neutrophil-to-lymphocyte ratio change predicts histological response to and oncological outcome of neoadjuvant chemotherapy for esophageal squamous cell carcinoma.

Authors:  Shota Hoshino; Masashi Takeuchi; Hirofumi Kawakubo; Ryota Kobayashi; Satoru Matsuda; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Yuko Kitagawa
Journal:  Esophagus       Date:  2022-01-21       Impact factor: 4.230

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.